Please login to the form below

Not currently logged in

BMS signs 10-year biologic manufacturing deal with Samsung

Agreement covers one of the pharma company's antibody cancer drugs

Bristol-Myers Squibb (BMS) buildingBristol-Myers Squibb (BMS) has signed a long-term agreement with Samsung BioLogics that will see the Korean firm manufacture one of its antibody cancer drugs.

Technology transfer and trial production of the candidate will begin almost immediately under a 10-year contract, with commercial production to follow as soon as the drug is approved.

Louis Schmukler, president of global manufacturing and supply at Bristol-Myers Squibb, said: "Our agreement with Samsung is an important part of our company's overall manufacturing and supply strategy focused on creating long-term relationships with high quality manufacturing partners around the world.

“This agreement increases our biologic manufacturing capacity to help ensure sufficient long-term supply of our commercial products.”

Earlier this year BMS outlined its plans for a major expansion of a US plant for its rheumatoid arthritis biologic Orencia (abatacept), which was launched in Europe in 2010, but will now outsource additional capacity for part of its oncology biologic pipeline.

This includes the fully humanised monoclonal antibody elotuzumab that BMS is developing with AbbVie, phase III results for which are due next year.

Nivolumab is also in development and phase III results of the potential first-in-class anti-PD-1 melanoma candidate were presented at this year's ASCO meeting. The drug has been predicted peak year sales of $1.2bn.

Financial terms were not disclosed for the deal, under which Samsung will manufacture the drug as its recently completed plant in Songdo Incheon, South Korea.

Tae-Han Kim, president and CEO of Samsung BioLogics, said: "We are pleased to announce this strategic manufacturing relationship with Bristol-Myers Squibb and look forward to delivering best-in-class manufacturing services with the highest global quality standards. 

“The relationship with Bristol-Myers Squibb represents the validation of our long-term commitment to the biopharmaceutical manufacturing industry.”

It's the second major pharma agreement for Samsung this year, after its joint venture with Biogen, Samsung Bioepis, agreed a deal in February to develop and commercialise biosimilars for Merck & Co.

30th July 2013

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...